Published in J Neurol Neurosurg Psychiatry on July 01, 1998
Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res (1998) 1.71
Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy. J Neurol Neurosurg Psychiatry (2007) 1.69
Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment. J Investig Med (2009) 1.27
Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry (2002) 1.13
'Hot cross bun' sign in a case of cerebrotendinous xanthomatosis: a rare neuroimaging observation. BMJ Case Rep (2013) 1.03
Tracking the neurodegeneration of parkinsonian disorders--a pilot study. Neuroradiology (2007) 1.03
How to diagnose MSA early: the role of magnetic resonance imaging. J Neural Transm (Vienna) (2005) 1.01
T2*-weighted MRI in diagnosis of multiple system atrophy. A practical approach for clinicians. J Neurol (2007) 0.93
Sensitivity of T2-weighted FSE sequences towards physiological iron depositions in normal brains at 1.5 and 3.0 T. Eur Radiol (2004) 0.93
Putaminal lesion in multiple system atrophy: postmortem MR-pathological correlations. Neuroradiology (2008) 0.91
Fragile x-associated tremor ataxia syndrome: the expanding clinical picture, pathophysiology, epidemiology, and update on treatment. Tremor Other Hyperkinet Mov (N Y) (2012) 0.86
Eye of the tiger-like MRI in parkinsonian variant of multiple system atrophy. J Neural Transm (Vienna) (2009) 0.83
'Hot cross bun' sign with leptomeningeal metastases of breast cancer: a case report and review of the literature. World J Surg Oncol (2015) 0.80
Diagnostic accuracy of apparent diffusion coefficient and 123I-metaiodobenzylguanidine for differentiation of multiple system atrophy and Parkinson's disease. PLoS One (2013) 0.80
Neuroinflammation in Multiple System Atrophy: Response to and Cause of α-Synuclein Aggregation. Front Cell Neurosci (2015) 0.77
The Diagnosis and Natural History of Multiple System Atrophy, Cerebellar Type. Cerebellum (2016) 0.77
Comparison of Cerebral Glucose Metabolism between Possible and Probable Multiple System Atrophy. J Mov Disord (2009) 0.76
Tremor in Multiple System Atrophy - a review. Tremor Other Hyperkinet Mov (N Y) (2013) 0.76
New MRI Biomarkers Advance the Characterization of Parkinson Disease. Eur Neurol Rev (2013) 0.75
Hyperintense putaminal rim at 1.5 T: prevalence in normal subjects and distinguishing features from multiple system atrophy. BMC Neurol (2012) 0.75
MR imaging in multiple system atrophy: its role in "splitting" parkinsonism. Ann Indian Acad Neurol (2008) 0.75
Clinical usefulness of MRI in multisystem atrophy. J Neurol Neurosurg Psychiatry (1999) 0.75
Hot cross bun sign in HIV-related progressive multifocal leukoencephalopathy. Ann Indian Acad Neurol (2013) 0.75
Diffusion tensor imaging in the characterization of multiple system atrophy. Neuropsychiatr Dis Treat (2016) 0.75
Hot cross bun sign following bilateral pontine infarction: a case report. J Mov Disord (2013) 0.75
Usefulness of Diffusion-Weighted MRI for Differentiation between Parkinson's Disease and Parkinson Variant of Multiple System Atrophy. J Mov Disord (2009) 0.75
Utility of susceptibility-weighted imaging in Parkinson's disease and atypical Parkinsonian disorders. Transl Neurodegener (2016) 0.75
Abnormal baroreceptor-mediated vasopressin release as possible marker in early diagnosis of multiple system atrophy. J Neurol Neurosurg Psychiatry (2004) 0.75
Spinocerebellar ataxia type 17 in a patient from an Indian kindred. J Neurol (2006) 0.75
Other dementias. Neuroradiology (2011) 0.75
Characteristic diffusion tensor tractography in multiple system atrophy with predominant cerebellar ataxia and cortical cerebellar atrophy. J Neurol (2016) 0.75
The measurement of observer agreement for categorical data. Biometrics (1977) 216.56
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology (1992) 6.03
Multiple system atrophy--the nature of the beast. J Neurol Neurosurg Psychiatry (1989) 3.41
Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology (1986) 1.50
Multiple system atrophy (Shy-Drager syndrome): MR imaging. Radiology (1986) 1.43
Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry (1994) 1.41
Olivopontocerebellar atrophy: MR diagnosis and relationship to multisystem atrophy. Radiology (1990) 1.38
Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes. Neurology (1989) 1.27
Magnetic resonance imaging in parkinsonism. Neurol Clin (1992) 1.09
Striatonigral degeneration: clinical, MRI, and pathologic correlation. Neurology (1990) 1.08
T2 relaxation time in patients with Parkinson's disease. Neurology (1993) 1.05
Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy. J Neurol Neurosurg Psychiatry (1994) 1.04
Multiple system atrophy. Clinical and MR observations on 42 cases. Ital J Neurol Sci (1993) 0.90
A study of parkinsonism in multiple system atrophy: clinical and MRI correlation. Acta Neurol Scand (1994) 0.90
Hemi-parkinsonism in multiple system atrophy: a PET and MRI study. J Neurol Sci (1992) 0.90
Is cranial computerized tomography useful in the diagnosis of multiple system atrophy? Mov Disord (1994) 0.87
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
A film of patients with movement disorders made in Queen Square, London in the Mid-1920s by Samuel Alexander Kinnier Wilson. Mov Disord (2011) 6.45
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology (1992) 6.03
Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci (1999) 5.01
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 4.33
Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1994) 4.24
Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet (1999) 3.94
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry (2000) 3.89
Striatonigral degeneration. A clinicopathological study. Brain (1990) 3.70
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry (1989) 3.53
Neural activity relating to generation and representation of galvanic skin conductance responses: a functional magnetic resonance imaging study. J Neurosci (2000) 3.49
Neural activity in the human brain relating to uncertainty and arousal during anticipation. Neuron (2001) 3.49
Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients. J Neurol Neurosurg Psychiatry (1991) 3.38
Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology (2001) 3.25
The impact of treatment with levodopa on Parkinson's disease. Q J Med (1980) 3.14
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology (2008) 3.10
Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology (2011) 3.10
A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol (1993) 3.00
Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet (1988) 2.80
Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain (1994) 2.77
Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol (1995) 2.76
Cerebral correlates of autonomic cardiovascular arousal: a functional neuroimaging investigation in humans. J Physiol (2000) 2.72
Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol (1996) 2.68
Cognitive deficits in the early stages of Parkinson's disease. Brain (1983) 2.65
International standards to document remaining autonomic function after spinal cord injury. Spinal Cord (2008) 2.65
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain (1992) 2.64
Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord (1997) 2.61
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet (2005) 2.56
Sequence interpretation. Functional annotation of mouse genome sequences. Science (2001) 2.54
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
PINK1 protein in normal human brain and Parkinson's disease. Brain (2006) 2.49
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 2.42
The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology (1997) 2.36
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet (1990) 2.30
The dystonias. BMJ (1990) 2.29
Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl (1993) 2.27
Spinal internuncial neurones in progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1979) 2.20
Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology (2000) 2.19
Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ (2000) 2.17
Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord (1998) 2.12
Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem (1997) 2.10
Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord (2000) 2.10
A gallium-68 radiopharmaceutical that is retained in myocardium: 68Ga[(4,6-MeO2sal)2BAPEN]+. J Nucl Med (1993) 2.06
Low-dose olanzapine for levodopa induced dyskinesias. Neurology (2000) 2.03
The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol (2012) 2.03
Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain (1990) 2.00
Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res (1995) 1.98
Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology (2001) 1.95
Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry (1989) 1.95
The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet (2005) 1.94
A clinico-pathological study of subtypes in Parkinson's disease. Brain (2009) 1.91
The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (2000) 1.89
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. Neurology (2001) 1.87
On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain (1984) 1.83
A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem (1997) 1.83
The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol (1989) 1.79
Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol (1995) 1.79
Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology (2005) 1.77
Acute movement disorders with bilateral basal ganglia lesions in uremia. Mov Disord (1998) 1.74
A clinical study of Gilles de la Tourette syndrome in the United Kingdom. J Neurol Neurosurg Psychiatry (1984) 1.72
Neurological deterioration in young adults with phenylketonuria. Lancet (1990) 1.71
Ramsay Hunt syndrome and coeliac disease: a new association? Mov Disord (1986) 1.69
Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry (1991) 1.69
Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry (2001) 1.68
Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem (1990) 1.66
Deprenyl in Parkinson's disease. Lancet (1977) 1.66
The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain (1998) 1.65
Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet (1997) 1.65
Performance of a 62Zn/62Cu generator in clinical trials of PET perfusion agent 62Cu-PTSM. J Nucl Med (2000) 1.65
Use of a mutant cell line to study the kinetics and function of O-linked glycosylation of low density lipoprotein receptors. Proc Natl Acad Sci U S A (1988) 1.62
Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology (2003) 1.61
Neuroanatomical basis for first- and second-order representations of bodily states. Nat Neurosci (2001) 1.61
New pathologic observations in juvenile onset parkinsonism with dystonia. Neurology (1991) 1.57
A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology (1988) 1.57
Tau gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Neurosurg Psychiatry (2004) 1.56